YOLFTbeta
Zai Lab Ltd

Zai Lab Ltd

ZLAB · NASDAQ · Healthcare / Biotechnology

24.60USD-1.44 (-5.53%)

Price History

Full chart

Market Stats

Previous Close26.04
Open25.75
Day Range23.43 – 25.94
52-Week Range15.96 – 27.50
Volume1.22M
Market Cap2.74B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.70
Dividend Yield0.00%
Beta0.72
50-Day Avg24.94
200-Day Avg20.98

About

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Ying Du Ph.D.
  • Employees1.78K
  • HeadquartersBuilding B, Pudong, China, 201203, USA
  • Websitehttps://www.zailaboratory.com

Leadership

  • Dr. Ying Du Ph.D.Founder, Chairperson & CEO · b. 1966
  • Dr. Rafael G. Amado M.D.President and Head of Global Research & Development · b. 1964
  • Dr. Yajing Chen Ph.D.Chief Financial Officer · b. 1968
  • Mr. Frazor Titus Edmondson III, J.D.Chief Legal Officer & Corporate Secretary · b. 1966
  • Ms. Christine ChiouSenior VP & Head of Investor Relations

Financials

Income Statement

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue000129.45K12.98M48.96M144.31M215.04M266.72M398.99M460.16M
Growth (%)----+9930.55%+277.04%+194.77%+49.01%+24.03%+49.59%+15.33%
Cost of Revenue00043.59K3.75M239.45M52.24M74.02M95.82M147.86M191.08M
Gross Profit00085.86K9.24M-190.49M92.07M141.02M170.90M251.13M269.07M
Gross Margin---66.33%71.13%-389.09%63.80%65.58%64.08%62.94%58.47%
Operating Expense16.35M38.53M51.39M141.85M212.43M111.31M792.14M545.38M537.48M533.25M492.65M
Operating Income-16.35M-38.53M-51.39M-141.77M-203.20M-301.80M-700.06M-404.36M-366.57M-282.12M-223.57M
Operating Margin----109514.01%-1564.88%-616.45%-485.10%-188.04%-137.44%-70.71%-48.59%
EBITDA-16.22M-38.33M-50.84M-138.45M-199.43M-297.16M-689.46M-434.84M-365.11M-242.99M-158.25M
EBITDA Margin----106949.81%-1535.88%-606.97%-477.76%-202.21%-136.89%-60.90%-34.39%
Net Income-18.02M-37.51M-50.38M-139.07M-183.37M-268.90M-704.47M-443.29M-334.62M-257.10M-175.54M
Net Income Margin----107433.56%-1412.16%-549.26%-488.16%-206.14%-125.46%-64.44%-38.15%
R&D13.59M32.15M39.34M120.28M142.22M222.71M573.31M286.41M265.87M234.50M220.90M
R&D as % of Total Revenue---92913.22%1095.29%454.90%397.27%133.19%99.68%58.77%48.01%
Interest Expense1.67M1.02M1.26M39.67K293.00K181.00K3.35M14.58M14.58M2.25M5.21M
Interest Expense % of Total Revenue---30.65%2.26%0.37%2.32%6.78%5.47%0.56%1.13%

Balance Sheet

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets13.94M88.91M249.63M301.99M355.15M1.30B1.61B1.22B1.04B1.19B1.17B
Total Liabilities32.31M140.46M14.46M50.91M60.49M128.29M230.00M174.54M240.18M344.86M456.88M
Total Equity-18.37M-51.55M235.17M251.08M294.66M1.17B1.38B1.05B796.12M840.90M715.50M
Cash13.16M83.95M229.66M62.95M75.93M442.12M964.10M1.01B790.15M449.67M679.57M
Total Debt---3.64M21.78M18.60M15.54M20.39M15.15M153.47M224.26M
Net Debt-13.16M-83.95M-229.66M-59.31M-54.15M-423.52M-948.56M-988.08M-775.00M-296.20M-455.31M

Cash Flow

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-11.46M-32.16M-32.37M-97.54M-191.01M-216.06M-549.23M-367.64M-198.18M-214.87M-150.79M
Investing Cash Flow-738.47K-2.73M-10.43M-212.55M-14.89M-554.83M249.96M420.02M-10.78M-375.19M307.87M
Financing Cash Flow18.28M106.20M187.86M144.15M219.30M1.13B820.20M-1.73M-6.43M349.89M72.35M
Capital Expenditure738.47K2.23M9.12M10.12M15.24M10.67M18.95M24.98M8.49M61.52M13.42M
Free Cash Flow-12.20M-34.39M-41.48M-107.66M-206.25M-226.72M-568.18M-392.63M-206.67M-276.39M-164.21M
Dividends Paid-------16.05M---
FCF to OCF106.44%106.93%128.17%110.37%107.98%104.94%103.45%106.80%104.28%128.63%108.90%
Dividend Paid to FCF--------4.09%---

Earnings

Report DateAug 4, 2016Feb 3, 2017Sep 21, 2017Nov 15, 2017Apr 30, 2018Sep 5, 2018Nov 28, 2018Mar 7, 2019May 29, 2019Sep 3, 2019Nov 27, 2019Mar 19, 2020Jun 3, 2020Aug 13, 2020Dec 2, 2020Mar 1, 2021May 10, 2021Aug 9, 2021Nov 9, 2021Mar 1, 2022May 10, 2022Aug 9, 2022Nov 9, 2022Mar 1, 2023May 9, 2023Aug 7, 2023Nov 7, 2023Feb 27, 2024May 8, 2024Aug 6, 2024Nov 12, 2024Feb 25, 2025May 8, 2025Aug 7, 2025Nov 6, 2025Feb 26, 2026May 12, 2026Aug 6, 2026Nov 5, 2026
EPS Estimate0.000.00--0.23-0.17-0.38-0.40-0.45-0.44-0.67-0.60-0.60-0.99-0.99-0.40-0.99-2.30-1.39-1.27-1.33-1.23-1.07-1.25-1.11-0.97-0.81-1.03-0.87-0.92-0.73-0.78-0.63-0.55-0.37-0.29-0.44-0.29-0.66-0.56
EPS Actual-0.24-0.76-0.74-0.21-0.25-0.26-0.33-0.68-0.67-0.43-0.60-0.68-0.99-0.67-0.40-0.40-2.64-1.76-1.01-2.17-0.86-1.44-1.68-0.65-0.51-1.25-0.71-0.98-0.50-0.82-0.42-0.80-0.45-0.37-0.33-0.46-0.46-0.46-
Surprise---8.70%-47.06%31.58%17.50%-51.11%-52.66%35.82%0.78%-13.33%0.01%32.32%0.45%59.78%-14.78%-26.62%20.47%-63.16%30.08%-34.58%-34.40%41.44%47.42%-54.32%31.07%-12.64%45.65%-12.33%46.15%-26.32%18.18%0.00%-13.79%-4.55%-58.13%30.30%-
Timing--After-hoursAfter-hoursPre-marketAfter-hours-Pre-market-Pre-market-Pre-market-Pre-market-Pre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-market

Key Statistics & Ratios

Market Cap2.74B
Enterprise Value2.39B
Trailing P/E0.00
Forward P/E0.00
Price / Sales6.09
Price / Book4.52
EPS-1.70
Book Value5.41
Revenue (TTM)449.61M
Gross Profit (TTM)16.98M
EBITDA-248.17M
Profit Margin-41.86%
Operating Margin-71.95%
Return on Equity-26.91%
Return on Assets-14.75%
Shares Outstanding124.15M
Shares Float97.11M
Beta0.72
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 11 analystsTarget 33.48
  • Strong Buy
    8
  • Buy
    2
  • Hold
    1

Ownership Breakdown

Institutions
34.98%
Insiders
1.93%
Retail / Other
63.09%

Top Institutional Holders

  • RTW INVESTMENTS, LLC
    6.57M5.86%
  • TCG Crossover Management, LLC
    6.14M5.47%
  • RA Capital Management, LLC
    5.74M5.12%
  • ADAR1 Capital Management LLC
    3.37M3.00%
  • FMR Inc
    2.82M2.51%
  • The Goldman Sachs Group Inc
    2.32M2.06%
  • Woodline Partners LP
    2.21M1.97%
  • Frazier Life Sciences Management, L.P.
    1.90M1.69%
  • BAMCO Inc
    1.62M1.45%
  • Two Sigma Investments LLC
    1.30M1.16%
  • Citadel Advisors Llc
    1.28M1.14%
  • Rock Springs Capital Management LP
    814.71K0.73%
  • BlackRock Inc
    664.46K0.59%
  • CAM Group Holding A/S
    510.00K0.45%
  • Jane Street Group LLC
    476.54K0.42%
  • B Group, Inc
    450.65K0.40%
  • Nantahala Capital Management, LLC
    400.00K0.36%

Top Fund Holders

  • Baron Emerging Markets Institutional
    1.33M1.07%
  • iShares Biotechnology ETF
    741.20K0.60%
  • C WorldWide Healthcare Select 1A
    510.00K0.41%